論文原著

英　文

• Konishi A, Samura O, Muromoto J, Okamoto Y, Takahashi H, Kasai Y, Ichikawa M, Yamada N, Kato N, Sato H, Hamada H, Nakanami N, Machi M, Ichizuka K, Sunami R, Tanaka T, Yonetani N, Kamei Y, Nagamatsu T, Matsumoto M, Tairaku S, Fujiwara A, Nakamura H, Harada T, Watanabe T, Sasaki S, Kawaguchi S, Minami S, Ogawa M, Miura K, Suzumori N, Kojima J, Kotani T, Sasaki R, Baba T, Toyofuku A, Endo M, Takeshita N, Taketani T, Sase M, Matsubara K, Hayata K, Hamada Y, Egawa M, Kakinuma T, Matsushima S, Kitagawa M, Shiga T, Kurashina R, Hamada H, Takagi H, Kondo A, Miharu N, Yamashita M, Horiya M, Morimoto K, Takahashi K, Okamoto A, Sekizawa A, Sago H.
  Prevalence of common aneuploidy in twin pregnancies.
  J Hum Genet. 67(5): 261-265, 2022
• Itakura A, Shoji S, Shigeru A, Kotaro F, Junichi H, Hironobu H, Kamei Y, Eiji K, Shintaro M, Ryu M, Mamoru M, Takeshi N, Masahiko N, Naruse K, Hidekazu N, Tomizo N, Mana OY, Yasumasa O, Kuniaki O, Koichiro S, Arihiro S, Shunji S, Kanji T, Shiro Y, Yoshiki K, Tsugio M, Makio S.
  Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and Gynecologists 2020 edition.
  J Obstet Gynaecol Res. 2022 Oct 17. doi: 10.1111/jog.15438. Online ahead of print.
• Oshina K, Kamei Y, Hori A, Hasegawa F, Taniguchi K, Migita O, Itakura A, Hata K.
  A novel FLNA variant in a fetus with skeletal dysplasia.
  Hum Genome Var. 9(1): 45. doi: 10.1038/s41439-022-00224-7.
• Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9.
  Survival with Cemiplimab in Recurrent Cervical Cancer.
  N Engl J Med. 386(6): 544-555, 2022
• Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V.
  Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
  Int J Gynecol Cancer. 32(1): 93-100, 2022
• Yonemori K, Yunokawa M, Ushijima K, Sakata J, Shikama A, Minobe S, Usami T, Enomoto T, Takehara K, Hasegawa K, Yamagami W, Yamamoto K, Han S, Dutta L, Orlowski R, Miura T, Makker V, Fujiwara K.
  Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
  Cancer Sci. 113(10): 3489-3497, 2022
• Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K.
  Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
  Cancer Sci. 113(11): 3877-3887, 2022
• LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK.
  Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
  Gynecol Oncol. 165(1): 82-89, 2022
• Yonemori K, Kuboki Y, Hasegawa K, Iwata T, Kato H, Takehara K, Hirashima Y, Kato H, Passey C, Buchbjerg JK, Harris JR, Andreassen CM, Nicacio L, Soumaoro I, Fujiwara K.
  Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
  Cancer Sci. 113(8): 2788-2797, 2022
• Matsuura K, Inoue K, Hoshino E, Yasuda M, Hasegawa K, Okada Y, Baba Y, Kozawa E.
  Utility of magnetic resonance imaging for differentiating malignant mesenchymal tumors of the uterus from T2-weighted hyperintense leiomyomas.
  Jpn J Radiol. 40(4): 385-395, 2022
• Nagawa K, Kishigami T, Yokoyama F, Murakami S, Yasugi T, Takaki Y, Inoue K, Tsuchihashi S, Seki S, Okada Y, Baba Y, Hasegawa K, Yasuda M, Kozawa E.
  Diagnostic utility of a conventional MRI-based analysis and texture analysis for discriminating between ovarian thecoma-fibroma groups and ovarian granulosa cell tumors.
  J Ovarian Res. 15(1): 65, 2022
• Onuki M, Yamamoto K, Yahata H, Kanao H, Yokota H, Kato H, Shimamoto K, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Watari H, Nakamura K, Ueda A, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Taguchi A, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group.
  Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
  Cancer Sci. 113(4): 1428-1434, 2022
• Kukimoto I, Onuki M, Yamamoto K, Yahata H, Aoki Y, Yokota H, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shimada M, Nakai H, Yoshida H, Motohara T, Yamazaki H, Nakamura K, Okunomiya A, Tasaka N, Ishikawa M, Hirashima Y, Shimoji Y, Mori M, Iwata T, Takahashi F, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group.
  Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia†.
  Jpn J Clin Oncol. 52(10): 1242-1247, 2022
• Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinieri S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I.
  Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
  Eur J Cancer. 2022 Dec 10;181:42-52. doi: 10.1016/j.ejca.2022.11.029. Online ahead of print.
• Ishihara O, Nelson SM, Arce J-C
  Comparison of ovarian response to follitropin delta in Japanese and white IVF/ICSI patients.
  Reprod Biomed Online. 44(1): 177-184, 2022
• Kuroda K, Katagiri Y, Ishihara O
  Optimal individualization of patient-oriented ovarian stu\imulation in Japanese assisted reproductive technology clinics, a review for unique setting with advanced-age patients.
  J Obstet Gynaecol Res 48(3): 521-532, 2022
• Alberico H, Fleischmann Z, Bobbitt T, Takai Y, Ishihara O, Seki H, Anderson RA, Telfer EE, Woods DC, Tilly JL
  Workflow optimization for identification of female germline or oogonial stem cells in human ovarian cortex using single-cell RNA sequence analysis.
  Sterm Cells 40(5): 523-536, 2022
• Tsukahara Y, Namba A, Kamada H, Torii S, Tabata S, Yamasawa F, Sato K.
  Factors that affect menarche in Japanese national-level track-and-field athletes.
  Am J Hum Biol.; 34(2):e23622.  doi: 10.1002/ajhb.23622, 2022
• Moto K, Goshozono M, Torii S, Namba A, Taguchi M
  Resting energy expenditure is lower in Japanese female athletes with menstrual disorders than in eumenorrheic athletes
  J Phys Fitness Sports Med, 11 (1): 35-42 ,2022
• Elsherbini M, Koga K, Maki E, Kumasawa K, Satake E, Taguchi A, Makabe T, Takeuchi A, Izumi G, Takamura M, Harada M, Hirata T, Hirota Y, Wada-Hiraike O, Osuga Y.
  Impact of Chronic Exposure to Endometriosis on Perinatal Outcomes: Establishment of a Mouse Model.
  Biomedicines. 10(10): 2627, 2022
• Elsherbini M, Koga K, Hiraoka T, Kumasawa K, Maki E, Satake E, Taguchi A, Makabe T, Takeuchi A, Izumi G, Takamura M, Harada M, Hirata T, Hirota Y, Wada-Hiraike O, Osuga Y.
  Establishment of a novel mouse model of adenomyosis suitable for longitudinal and quantitative analysis and perinatal outcome studies.
  Sci Rep. 12(1): 17515, 2022
• Tamaru S, Jwa SC, Ono Y, Seki H, Matsui H, Fujii T, Iriyama T, Doi K, Sameshima H, Naruse K, Kobayashi H, Yoshida R, Nishi H, Hirata Y, Fukushima K, Hirakawa T, Nakano Y, Asakawa Y, Tsunoda Y, Oda T, Nii S, Fujii T, Kinoshita K, Kamei Y.
  Feasibility of a mobile cardiotocogram device for fetal heart rate self-monitoring in low-risk singleton pregnant women.
  J Obstet Gynaecol Res. 48(2): 385-392, 2022
• Jwa SC, Namba A, Tamaru S, Kuwahara A, Sago H, Ishihara O, Kamei Y.
  Down syndrome live births following assisted reproductive technology in Japan: a nationwide survey between 2007 and 2016.
  J Assist Reprod Genet. 39(7): 1625-1631, 2022
• Ogawa K, Jwa SC, Morisaki N, Sago H.
  Risk factors and clinical outcomes for placenta accreta spectrum with or without placenta previa.
  Arch Gynecol Obstet. 305(3): 607-615, 2022
• Maeda E, Jwa SC, Kumazawa Y, Saito K, Iba A, Yanagisawa-Sugita A, Kuwahara A, Saito H, Terada Y, Fukuda T, Ishihara O, Kobayashi Y.
  Out-of-pocket payment and patients’ treatment choice for assisted reproductive technology by household income: a conjoint analysis using an online social research panel in Japan.
  BMC Health Serv Res. 2022 Aug 27;22(1):1093. doi: 10.1186/s12913-022-08474-5.
• Yamada M, Ishikawa T, Iwasa T, Oishi H, Osuka S, Oka K, Ono S, Ono M, Orisaka M, Kanasaki H, Kawano Y, Kawamura K, Kishi H, Kimura F, Kuroda S, Kuwahara A, Kobayashi H, Komiya A, Saito H, Sato K, Sato S, Shiraishi K, Shirasawa H, Suzuki T, Takai Y, Takae S, Takahashi T, Takiuchi T, Tachibana M, Tamura I, Tamura H, Jwa SC, Baba T, Harada M, Hirata T, Fukui A, Fukuda Y, Fukuhara S, Maruyama T, Yumura Y, Yoshino O, Hirota Y, Tsujimura A, Kuji N, Osuga Y.
  Guidelines for Reproductive Medicine in Japan.
  Reprod Med Biol. 21(1): e12483, 2022
• Miyazaki K, Jwa SC, Katayama E, Tamaru S, Ishihara O, Kamei Y.
  Postoperative C-reactive protein as a predictive marker for surgical site infection after cesarean section: Retrospective analysis of 748 patients at a Japanese academic institution.
  PLoS One. 17(9): e0273683, 2022
• Ishida M, Uchida N, Yabuno A, Hasegawa K, Mizunuma N, Takahashi T, Onishi H.
  Opioid withdrawal syndrome developing after long-term administration of naldemedine.
  Palliat Support Care. 2022 May 11:1-3. doi: 10.1017/S147895152200044X. Online ahead of print.
• Sato M, Sato S, Shintani D, Hanaoka M, Ogasawara A, Miwa M, Yabuno A, Kurosaki A, Yoshida H, Fujiwara K, Hasegawa K.
  Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
  BMC Cancer. 22(1): 59, 2022
• Sato S, Matsushita H, Shintani D, Kobayashi Y, Fujieda N, Yabuno A, Nishikawa T, Fujiwara K, Kakimi K, Hasegawa K.
  Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer.
  BMC Cancer. 22(1): 437, 2022
• Nagasawa S, Ikeda K, Shintani D, Yang C, Takeda S, Hasegawa K, Horie K, Inoue S.
  Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells.
  Int J Mol Sci. 23(2): 689, 2022
• Matsuda N, Jwa SC, Tamura S, Suzuki H, Takamura M, Namba A, Kajihara T, Okagaki R, Kamei Y, Ishihara O.
  Factors associated with an unfavorable clinical course in hospitalized patients with pelvic inflammatory disease: a retrospective cohort study of 117 patients from a Japanese academic institution
  BMC Womens Health. 22(1): 348, 2022
• Kusama K, Satoyoshi A, Azumi M, Yoshie M, Kojima J, Mizuno Y, Ono M, Nishi H, Kajihara T, Tamura K.
  Toll-like receptor signaling pathway triggered by inhibition of serpin A1 stimulates production of inflammatory cytokines by endometrial stromal cells.
  Front Endocrinol (Lausanne). 2022 Aug 24;13:966455. doi: 10.3389/fendo.2022.966455. eCollection 2022.

邦　文

• 西岡暢子、河村　真、福島悦雄、丸山正統、柏崎祐士、高井　泰、亀井良政、平田善康
  新型コロナウイルス流行下に開設した「妊産婦心のケアオンライン相談窓口」について
  埼玉県医学会雑誌56(1): 353-356, 2022
• 御所園実花、田口素子、難波　聡、鳥居　俊
  正常月経周期を有する大学生女性アスリートにおける周期によるエナジー・アベイラビリティーの変化
  日本臨床スポーツ医学会誌30(1): 96-103, 2022
• 田丸俊輔、左　勝則、関　博之、松井遥香、藤井達也、入山高行、土井宏太郎、鮫島　浩、成瀬勝彦、吉田梨恵、西　洋孝、平田善康、福嶋恒太郎、中野義宏、藤井知行、木下勝之、亀井良政
  在宅妊婦におけるモバイル型CTGモニターの有用性に関する検討
  日本周産期・新生児医学会雑誌57(4): 840-844, 2022
• 黒崎　亮、長谷川幸清、柴崎智美、番場　宏、藤原恵一
  埼玉県における、受診率からみた子宮頸がん検診の現状と課題
  埼玉産科婦人科学会雑誌52(1): 121-126, 2022
• 前田恵理、石原　理、左　勝則、李　廷秀、小林廉毅
  韓国における人工授精および生殖補助医療の公費負担状況　保険適用の背景と影響に関する訪問調査
  公衆衛生86(1): 84-90, 2022

論文総説

邦　文

• 亀井良政
  【新型コロナウイルス感染症が産婦人科診療に与えた影響】【III.診療体制】埼玉県の取り組み
  産科と婦人科89(3): 280-285, 2022
• 早川　直、高田和秀、相澤[小峯]志保子、亀井良政、早川　智
  妊娠とコロナウイルス感染症
  母性衛生62(4): 学28-学33, 2022
• 亀井良政
  【胎児発育のすべて-FGRから巨大児まで】発育異常の評価　FGRの定義と原因総論
  臨床婦人科産科76(9): 838-842, 2022
• 亀井良政
  【191の疑問に答える　周産期の栄養】母体の栄養　母体栄養の基礎　市販飲料水（軟水・硬水,スポーツドリンク）や嗜好品の種類と選び方
  周産期医学52(増刊): 261-263, 2022
• 亀井良政
  【帝王切開分娩のすべて-この1冊でわかるNew Normal Standard】帝王切開の歴史
  臨床婦人科産科76(12): 1168-1173, 2022
• 永田一郎
  手術手技　骨盤臓器脱に対する腟閉鎖術の術後再発とその防止策
  日本女性骨盤底医学会誌18(1): 49-57, 2022
• 石原　理
  ヒト胚に対する介入への社会的受容
  Hormone Frontier in Gynecology 29(1): 57-61, 2022
• 石原　理
  親子関係に関する民法の特例法について
  臨床婦人科産科76(4): 6-8, 2022
• 石原　理
  卵子提供によって出生した子の親子関係
  臨床婦人科産科76(6): 518-522, 2022
• 石原　理
  「約束のかたち」について
  年報医事法学37 :5-7, 2022
• 石原　理
  出自を知る権利
  Hormone Frontier in Gynecology 29(4): 53-56, 2022
• 難波　聡
  【今妊娠初期の経過異常とその対処-流産・異所性妊娠・絨毛性疾患の診断と治療】異所性妊娠　異所性妊娠の薬物療法の適応と治療法
  臨床婦人科産科76(2): 239-242, 2022
• 難波　聡
  【今妊娠初期の経過異常とその対処-流産・異所性妊娠・絨毛性疾患の診断と治療】異所性妊娠　異所性妊娠の待機療法の基準
  臨床婦人科産科76(2): 243-245, 2022
• 難波　聡
  知って支援力アップ!妊娠・出産・産後にまつわる最近の話題(第8回)　新型出生前診断NIPT
  チャイルドヘルス25(7): 536-538, 2022
• 難波　聡
  【胎児発育のすべて-FGRから巨大児まで】原因からみた胎児発育の異常　FGRと胎盤限局性モザイク
  臨床婦人科産科76(9): 855-860, 2022
• 高村将司、甲賀かをり
  【ここまで進んだ産婦人科関連の予防医学】生殖分泌　子宮内膜症再発予防（解説）
  産科と婦人科89(8): 854-858, 2022
• 左　勝則
  【生殖補助医療の進歩と周産期医療】生殖補助医療(ART)の立場から　ART妊娠の周産期予後（解説）
  周産期医学52(3): 345-347, 2022
• 左　勝則、梶原　健、石原　理
  【産婦人科における素朴な疑問と解説（1）婦人科編】婦人科　凍結融解胚移植は母体や児に影響しないの？
  産科と婦人科89(10): 1094-1097, 2022
• 石橋敬一郎、側島久典、辻　美隆、米岡裕美、木下牧子、中島宏昭、村松俊裕、小山政史、魚住尚紀、小川智也、黒崎　亮、椎橋実智男、三村俊英、森　茂久
  遠隔システムを用いたオンライン臨床研修指導医講習会の試み
  埼玉医科大学雑誌48(2): 85-91, 2022
• 三輪真唯子、長谷川幸清
  Gynecologic Cancer　婦人科腫瘍　子宮頸癌治療の過去、現在、未来　III.子宮頸癌薬物療法の変遷と今後期待される新規薬剤
  癌と化学療法49(2): 155-160, 2022
• 鷹野夏子、亀井良政
  【帝王切開分娩のすべて-この1冊でわかるNew Normal Standard】術式の工夫　開腹時の工夫-膀胱損傷を防ぐために
  臨床婦人科産科76(12): 1184-1187, 2022
• 新谷大輔、長谷川幸清
  PARP阻害薬のコンビネーション治療（化学療法,分子標的治療,免疫療法）；作用機序と可能性
  腫瘍内科30(4): 442-449, 2022